Enabling precision medicine

Olink Proteomics at a glance

Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research which previously could not be done and lowers costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease.

Year acquired

2018

Sector

Life science

Revenue

EUR 133 m

Location

Sweden

Employees

581

Investment themes

Changing Demographics

Key developments in 2022

In 2022, Olink had strong operational perfor­mance with a number of material, positive out­puts. From a customer perspective, Olink’s base has grown from >630 to >850 biopharma and prestigious academic institutions. In biopharma, Olink has expanded its customer base from all of the top 20 institutions to many of the top 40.

The challenges we face

We currently suffer from ineffective medication due to a lack of understanding of the biology of diseases. The shift from the "one size fits all" approach to precision medicine is a colossal challenge for science. Delivering the right treatment, to the right patient at the appropriate time requires developing protein biomarker panels to improve our understanding of human biology and optimize the development of new drugs and treatments.

0%

of patients receive no benefit from treatment with top 10 best-selling drugs in the world.

0%

of OECD GDP is spent on healthcare

How does Olink help?

Reality today

We do not understand the biology of many leading diseases—in par­ticular the role of proteins—which prevents us from developing effec­tive medication and delivering precision treatment.

Olink approach

Olink’s proprietary Proximity Extension Assay (PEA) technology enables research­ers to efficiently analyze large numbers of proteins with high throughput analysis, advancing our understanding of protein interactions in human diseases and our ability to develop new therapies.

Aspirational future

Deeper understanding of human biology and disease allows us to de­velop and deliver the most effective treatments for patients.

Who is impacted?

Researchers are impacted directly through more effective tools to understand human biology. Patients are impacted indirectly through break­throughs in treatments.

What are the impact considerations?

Additionality

By providing a truly unique technology to the market, Olink makes a major contribution to the research enabling advancements in precision medicine.

Risks

Olink’s impact depends in part on how its customers in academia and biopharma choose to use its tools. Olink can engage customers to help ensure that the research it enables trans­lates into treatment innovations and eventually patient outcomes.




SDG alignments

SDG 3

KPI reporting

Revenue (EURm)

2022:
+0%
129m
2021:
84m
2020:
49m

Number of publications

2022:
+0%
1 196
2021:
791
2020:
500

Customer accounts served

2022:
+0%
926m
2021:
750m
2020:
637m